Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Wang, Yi; Wang, Yan; Li, Jialong; Li, Jue; Che, Guowei

doi:10.1155/2020/3608241

Cited by 23 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing several publications that investigated the impact of PIK3CA on lung cancer, Wang et al concluded that PIK3CA mutation may not only affect lymph node metastasis but might also serve as prognostic factor in NSCLC. Additionally, smoking may be correlated with an increase in PIK3CA expression [ 28 ]. Besides the catalytic subunit we also found the phosphoinositide-3-kinase regulatory subunits 1 and 2 to be aberrantly methylated in tumor specimens of our biopsy cohort.…”

Section: Discussionmentioning

confidence: 99%

DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer

Goldmann

Schmitt²,

Müller³

et al. 2021

Clin Epigenet

View full text Add to dashboard Cite

Background Lung cancer is the leading cause of cancer-related death in most western countries in both, males and females, accounting for roughly 20–25% of all cancer deaths. For choosing the most appropriate therapy regimen a definite diagnosis is a prerequisite. However, histological characterization of bronchoscopic biopsies particularly with low tumor cell content is often challenging. Therefore, this study aims at (a) determining the value of DNA methylation analysis applied to specimens obtained by bronchoscopic biopsy for the diagnosis of lung cancer and (b) at comparing aberrantly CpG loci identified in bronchoscopic biopsy with those identified by analyzing surgical specimens. Results We report the HumanMethylation450-based DNA methylation analysis of paired samples of bronchoscopic biopsy specimens either from the tumor side or from the contralateral tumor-free bronchus in 37 patients with definite lung cancer diagnosis and 18 patients with suspicious diagnosis. A differential DNA methylation analysis between both biopsy sites of patients with definite diagnosis identified 1303 loci. Even those samples were separated by the set of 1303 loci in which histopathological analysis could not unambiguously define the dignity. Further differential DNA methylation analyses distinguished between SCLC and NSCLC. We validated our results in an independent cohort of 40 primary lung cancers obtained by open surgical resection and their corresponding controls from the same patient as well as in publically available DNA methylation data from a TCGA cohort which could also be classified with high accuracy. Conclusions Considering that the prognosis correlates with tumor stage at time of diagnosis, early detection of lung cancer is vital and DNA methylation analysis might add valuable information to reliably characterize lung cancer even in histologically ambiguous sample material.

show abstract

Section: Discussionmentioning

confidence: 99%

DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer

Goldmann

Schmitt²,

Müller³

et al. 2021

Clin Epigenet

View full text Add to dashboard Cite

show abstract

“…6) Previous studied proved that this protein serves as oncogene in tumor genesis and development of esophageal cancer at the levels of genetic mutation and epigenetics. Recent researches demonstrate that PIK3CA mutation has been found in a large variety of human tumors, Furthermore, the PIK3CA gene has been recognized as a candidate driver gene of lung squamous cell carcinoma and may contribute to the tumor cell growth and development of NSCLC (Wang, Wang, Li, Li, & Che, 2020).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of TGF β & β – Catenin Components in Various Human Cancer Tissues

Daraghmeh

Mansour

Kmail

et al. 2021

JAB

View full text Add to dashboard Cite

Studies over the last years revealed significant insights into the β-Catenin & TGF β signal transduction pathways and that such pathways are abnormal activated in abundant cancer types. According to the straight forward effect of these pathways in various tumor types, both pathways are currently considered targets for innovative cancer therapies. This view study emphasizes 13 proteins that are implicated in these two pathways. As there has been widespread research into the proteins that involved in these pathways, we have utilized data existing in the Human Protein Atlas database in this paper to examine the expression of 53 crucial proteins that are recognized to be involved in the activation of these pathways in a distinct group of 45 cancer types. Our findings revealed notably that the proteins (SKIL, SHC, ERK1/2, RAS, PI3K (PIK3CA), SMAD8, ACVR2A/1B SNON, AKT, and SMAD3, from TGF β and (RNF43, SNAIL1 and DVl) for β catenin show high expression in most caner tissues. Our results strongly suggest that these proteins might have the ability to act as potential objects for remedies and provide perception into the molecular basis of cancer.

show abstract

“…Deregulation of the PI3K/AKT/mTOR signaling pathway by either the mutation or amplification of genes involved in the PI3K pathway, loss of the tumor suppressor PTEN, or overactivation of RTKs, has been observed in various cancer cells, contributing to tumor progression and metastasis [ 48 , 49 , 50 , 51 ]. PIK3CA , the gene encoding the catalytic subunit of the PI3Kα isoform, is frequently mutated in various human cancers, including breast, ovarian and lung cancers [ 52 , 53 , 54 ]. Two hotspot E542K and E545K mutations in the p110 subunit alter the conformation of PI3Kα, in which an active site of PI3Kα is exposed at the membrane and is subsequently activated [ 55 , 56 ].…”

Section: Pi3k/akt/mtor Signaling Pathwaymentioning

confidence: 99%

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products

2021

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers and has a high mortality rate. Due to its high incidence, the clinical management of the disease remains a major challenge. Several reports have documented a relationship between the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway and lung cancer. The recognition of this pathway as a notable therapeutic target in lung cancer is mainly due to its central involvement in the initiation and progression of the disease. Interest in using natural and synthetic medications to target these signaling pathways has increased in recent years, with promising results in vitro, in vivo, and in clinical trials. In this review, we focus on the current understanding of PI3K/AKT/mTOR signaling in tumor development. In addition to the signaling pathway, we highlighted the therapeutic potential of recently developed PI3K/AKT/mTOR inhibitors based on preclinical and clinical trials.

show abstract

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cited by 23 publications

References 34 publications

DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer

DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer

Comprehensive Analysis of TGF β & β – Catenin Components in Various Human Cancer Tissues

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products

Contact Info

Product

Resources

About